Summary

Armodafinil 150 mg daily for 8 weeks as an adjuvant with mood stabilizers and/or antipsychotic drugs improved depressive symptoms associated with bipolar I disorder. The benefits, however, were not statistically significant compared with placebo. The findings of a multi-institutional, international, Phase 3, randomized, double-blind, placebo-controlled trial are discussed in this article [APA 2014 (poster NR6-038); NCT01305408].